Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2016/08/03 17:07:19」(JST)

wiki en

Dyslipidemia is an abnormal amount of lipids (e.g.,triglycerides, cholesterol and/or fat phospholipids) in the blood. In developed countries, most dyslipidemias are hyperlipidemias; that is, an elevation of lipids in the blood. This is often due to diet and lifestyle. Prolonged elevation of insulin levels can also lead to dyslipidemia. Likewise, increased levels of O-GlcNAc transferase (OGT) may cause dyslipidemia.

Classification

Physicians and basic researchers classify dyslipidemias in two distinct ways:

Phenotype, or the presentation in the body (including the specific type of lipid that is increased)
Etiology, or the reason for the condition (genetic, or secondary to another condition). This classification can be problematic, because most conditions involve the intersection of genetics and lifestyle issues. However, there are a few well-defined genetic conditions that are usually easy to identify.

Fredrickson Classification:^[1]

Phenotype	I	IIa	IIb	III	IV	V
Elevated Lipoprotein	Chylomicron	LDL	LDL and VLDL	IDL	VLDL	VLDL and chylomicrons

Types

	Increases	Decreases
Lipid	Hyperlipidemia: lipids Hypercholesterolemia: cholesterol. Familial hypercholesterolemia is a specific form of hypercholesterolemia due to a defect on chromosome 19 (19p13.1-13.3). Hyperglyceridemia: glycerides Hypertriglyceridemia: triglycerides	Hypolipidemia Hypocholesterolemia: cholesterol
Lipoprotein	Hyperlipoproteinemia: lipoproteins (usually LDL unless otherwise specified) Honemia: chylomicrons	Hypolipoproteinemia: lipoproteins Abetalipoproteinemia: beta lipoproteins Tangier disease: high density lipoprotein
Both	Combined hyperlipidemia: both LDL and triglycerides

References

^ Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation 1965;31:321-327.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 腎移植後の脂質異常 lipid abnormalities after renal transplantation
2. 降圧剤と脂質 antihypertensive drugs and lipids
3. スタチンと慢性腎臓病 statins and chronic kidney disease
4. 糖尿病の治療におけるチアゾリジン thiazolidinediones in the treatment of diabetes mellitus
5. 心血管学の最新情報 whats new in cardiovascular medicine

English Journal

Waist circumference as a vital sign in cardiology 20 years after its initial publication in the american journal of cardiology.

Després JP.
The American journal of cardiology.Am J Cardiol.2014 Jul 15;114(2):320-3. doi: 10.1016/j.amjcard.2014.04.043. Epub 2014 May 2.
In 1994, we reported in The American Journal of Cardiology that a simple anthropometric measurement, waist circumference, was related to the amount of abdominal visceral adipose tissue measured by computed tomography. An elevated waist circumference was also found to be associated with several featu
PMID 24878123

Combinational effects of farnesoid X receptor antagonist and statin on plasma lipid levels and low-density lipoprotein clearance in guinea pigs.

Amano Y1, Ishikawa E2, Shinozawa E2, Shimada M2, Miura S2, Adachi R2, Tozawa R2.
Life sciences.Life Sci.2014 Jul 11;108(1):7-12. doi: 10.1016/j.lfs.2014.04.029. Epub 2014 May 5.
AIMS: We previously reported anti-dyslipidemic effects of a farnesoid X receptor antagonist in monkeys. In this study, we compared the cholesterol-lowering effects of single and combined administration of a farnesoid X receptor antagonist, compound-T8, and the 3-hydroxy-3-methylglutaryl-coenzyme A r
PMID 24805868

Niacin activates the G protein estrogen receptor (GPER)-mediated signalling.

Santolla MF1, De Francesco EM1, Lappano R1, Rosano C2, Abonante S3, Maggiolini M4.
Cellular signalling.Cell Signal.2014 Jul;26(7):1466-75. doi: 10.1016/j.cellsig.2014.03.011. Epub 2014 Mar 21.
Nicotinic acid, also known as niacin, is the water soluble vitamin B3 used for decades for the treatment of dyslipidemic diseases. Its action is mainly mediated by the G protein-coupled receptor (GPR) 109A; however, certain regulatory effects on lipid levels occur in a GPR109A-independent manner. Th
PMID 24662263

Japanese Journal

Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes:A Subgroup Analysis of the J-BENEFIT Study

Hirose Takahisa,Teramoto Tamio,Abe Kazunori,Taneyama Takehiko,J-BENEFIT study group
Journal of Atherosclerosis and Thrombosis advpub(0), 2015
… Aim: Our previous "J-BENEFIT (Japan BEzafibrate cliNical EFfectIveness and Tolerability)" study demonstrated that bezafibrate improves blood lipid profiles and glucose control in dyslipidemic patients with diabetes. …
NAID 130004845546

Autosomal Recessive Hypercholesterolemia: A Mild Phenotype of Familial Hypercholesterolemia: Insight from the Kinetic Study using Stable Isotope and Animal Studies

Tada Hayato,Kawashiri Masa-aki,Nohara Atsushi,Inazu Akihiro,Kobayashi Junji,Mabuchi Hiroshi,Yamagishi Masakazu
Journal of Atherosclerosis and Thrombosis 22(1), 1-9, 2015
… This review summarizes current understanding regarding ARH and its causative gene, LDLRAP1, and attempts to provide new insight into novel pharmacological targets for treating dyslipidemic patients. …
NAID 130004845485

Increased Cardio-ankle Vascular Index in Hyperlipidemic Patients without Diabetes or Hypertension

Dobsak Petr,Soska Vladimir,Sochor Ondrej,Jarkovsky Jiri,Novakova Marie,Homolka Martin,Soucek Miroslav,Palanova Petra,Lopez-Jimenez Francisco,Shirai Kohji
Journal of Atherosclerosis and Thrombosis 22(3), 272-283, 2015
… The LDL cholesterol level was also calculated, and the CAVI was measured using the VaSera® 1500 system.Results: The CAVI values were significantly higher in the dyslipidemic patients (8.08, 95% CI 6.00-10.05) than in the controls (7.11, 95% CI 5.77-9.05; …
NAID 130004721919

「異脂肪血症」

Dyslipidemia
Classification and external resources
Specialty	Cardiology
ICD-10	E78
ICD-9-CM	272
DiseasesDB	33452
MeSH	D050171
	[edit on Wikidata]

　　[★]

英: dyslipidemia、dyslipidaemia、dyslipidemic
関: リピドーシス、脂質代謝異常、異リポ蛋白血症、脂質蓄積症

[1] Fredrickson DS, Lees RS. A system for phenotyping hyperlipoproteinemia. Circulation 1965;31:321-327.

匿名

検索

案内

案内

dyslipidemic